Pharmacoeconomics and Pharmacoepidemiology: Curious bedfellows or a match made in heaven?

PharmacoEconomics

Volumn 24, Issue 11, 2006, Pages 1079-1086

  Briggs, Andrew H ^a   Levy, Adrian R ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH PRACTITIONER; HUMAN; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MEDICAL RESEARCH; MORBIDITY; MORTALITY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT OUTCOME;

EID: 33750587609     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624110-00005     Document Type: Conference Paper

References (27)

1. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021-9
2. Staffa JA, Chang J, Green L. Cerivastatin and fatal reports of rhabdomyolysis. N Engl J Med 2002; 346: 539-40
3. Last JM. A dictionary of epidemiology. Oxford: Oxford University Press, 2000
4. Ioannidis JPA, Lau J. Improving safety reporting from randomised trials. Drug Saf 2002; 25: 77-84
5. Graham DJ, Waller PC, Kurz X. A view from regulatory agencies. In: Strom BL, editor. Pharmacoepidemiology. Chichester: John Wiley & Sons, 2000: 109-24
6. Strom BL. Study designs available for pharmacoepidemiology studies. In: Strom BL, editor. Pharmacoepidemiology. Chichester: John Wiley & Sons, 2000: 17-29
7. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-53
8. Suissa S. The case time-control design. Epidemiology 1995; 6: 248-53
9. Langholz B, Thomas DC. Nested case-control and case-cohort methods of sampling from a cohort: a critical comparison. Am J Epidemiol 1990; 131: 169-76
10. Lynd LD, O'Brien BJ. Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis. J Clin Epidemiol 2004; 57: 795-803
11. Sutton AJ, Cooper NJ, Abrams KR, et al. A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty. J Clin Epidemiol 2005; 58: 26-40
12. Willan AR, Briggs AH. Statistical analysis of cost-effectiveness data. Chichester: Wiley, 2006
13. Geerts W, Jay R, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335: 701-7
14. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990; 10: 212-4
15. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ 1995; 311: 1356-9
16. Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. CMAJ 1993; 148: 913-7
17. Weinstein MC. From cost-effectiveness ratios to resource allocation: where to draw the line? In: Sloan FA, editor. Valuing health care. Cambridge: Cambridge University Press, 1995: 77-98
18. Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia (PA): WB Saunders Company, 1980
19. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716-21
20. Raiffa H, Schlaifer R. Applied statistical decision theory. Boston (MA): Harvard Business School, 1961
21. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
22. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
23. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics 1996; 9: 113-20
24. Culyer AJ, McCabe CJ, Briggs A, et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Policy. In press
25. Rawlins MD, Culyer AJ. National institute for clinical excellence and its value judgments. BMJ 2004; 329: 224-7
26. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13
27. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523-34